Immunology, Transplantation and Infectious diseases
AIRC 5x1000 | Advanced Therapies for Liver Metastases
Colorectal and pancreatic ductal adenocarcinomas are the second and fourth most common cause of cancer death, respectively. 
Patients affected by these cancers often die of liver metastases, which represent the major unmet clinical need for these malignancies.
Based on preliminary data and published observations, we believe that innovative cancer immune gene and cell therapy approaches might overcome the tolerogenic liver microenvironment and represent powerful therapeutic tools for colorectal and pancreatic ductal adenocarcinomas derived liver metastases.
The program gathers together 14 basic research units – working on topics ranging from tumor immunology to gene therapy, from genomics to advanced imaging – and 5 clinical units of IRCCS Ospedale San Raffaele.
It exploits shared state-of-the-art omics, including at single-cell level, advanced imaging, flow cytometry, and histological platforms, and takes advantage of the roadmaps previously established at San Raffaele for the development of gene and cell therapies in other indications.
Download the complete GANTT of the program.
A lay (and up-to-date) description of the program, in Italian, can be found here.
Mission
The ultimate mission of this AIRC translational program is to develop, validate and implement clinical testing of new advanced therapy medicinal products (ATMP), based on immune gene and cell therapies, for liver metastases that arise from colorectal and pancreatic ductal adenocarcinomas.
Experimental Design
The proposal spans 7 years and is built on 4 highly integrated programs:
- Program 1 (coordinators: Paolo Dellabona; Luca Aldrighetti) aims at unraveling - using biological samples collected through an observational clinical study (LiMeT) - the immune infiltrate and cancer cell profiles in liver metastasis from colorectal and pancreatic ductal adenocarcinomas, to identify tumor associated antigens and immune suppressive and regulatory pathways to be targeted in these two diseases.
Results of this discovery program will progressively shape two independents but potentially combinatorial translational programs, tackling hepatic metastasis by rational and targeted modification of the immune effectors within the tumor microenvironment, through state-of-the-art cell therapies and gene transfer/editing tools. - Program 2 (coordinators: Chiara Bonini; Massimo Falconi) aims at harnessing T cells with genetic tools that allow their retargeting against cancer cells, while ensuring resistance to the immunosuppressive tumor microenvironment.
- Program 3 (coordinators: Luigi Naldini; Michele Reni) will modify the immunosuppressive microenvironment through novel targeted in vivo gene therapies, aimed at enhancing spontaneous innate and adaptive immunity against the tumor, as well as the efficacy of exogenous T cell responses.
The most promising ATMPs generated by the 3 programs will be selected for further development in a successive phase (Program 4): they will be stringently assessed for efficacy and toxicity in preclinical models and the best performing products will be prioritized for early phase clinical trials launched towards the end of the funding period.
Achievements
By matched and multi-level analyses on patients’ biological samples, Program 1 has:
- identified different immunoregulatory receptors and molecules involved in the immune suppression and exhaustion distinctive of hepatic metastases (first milestone achieved);
- selected several tumor antigens eligible for CAR development and/or TCR redirection (second milestone achieved).
By an optimized pipeline for T cell gene editing (patent application submitted), Program 2 has established the genetic deletion of those immunoregulatory receptors identified by Program 1. Moreover, new CAR- and TCR-T cell products have been generated and are now under functional and safety validation, either administered alone or in combination with novel agents able to enhance adoptive T cell therapy.
Program 3 has designed and produced different peptide-based formulations for tumor/stroma targeting and a tunable lentivirus-based platform for liver-targeted cytokine delivery (patent application submitted), by which a candidate antitumoral cytokine has been selectively expressed in liver metastases of tumor-bearing mice, exerting promising therapeutic effects in the absence of systemic toxicity.
The institutional biobank (Center of Biological Resources, CRB) assures the availability of several biological specimens from patients enrolled in LiMeT clinical study (over 400 patients since its authorization in November 2019), including follow-up samples, that allow cross-sectional and longitudinal analyses planned by Program 1.
Patients’ clinical data are collected at enrollment and during follow-up visits and archived in a GDPR-compliant intramural database (Cohort Genomics Platform, CGP), providing clinical correlates of experimental results from Program 1.
Different ex-vivo and in vivo models have been developed and shared by the AIRC5x1000 consortium, to recapitulate and intervene on hepatic metastases of colorectal and pancreatic ductal adenocarcinomas. They will be instrumental for efficacy and toxicity studies planned by Program 2 and 3.
In March 2022 the Program has passed the 3rd-year midterm review by a panel of 9 international experts in translational oncology, clinical immunology and genetics, who confirmed the viability of the projects and endorsed the merit of clinical and research teams. The next midterm review will be in the 5th year.
Last updated: 30.12.2022
Prof. Dr. Hana Algül
Technische Universität München, Munich
Prof. Dr. Dirk Busch
Technische Universität München, Munich
Dr. Luca Gianni
Gianni Bonadonna Foundation, Milan
Prof. Francesco Sclafani (since February 2023)
Institut Jules Bordet, Brussels
Prof. Nicola Valeri (former)
The Institute of Cancer Research, London
Imperial College London, London​
Beta cell biology
Lorenzo Piemonti, Group leader
Dynamics of immune responses
Matteo Iannacone, Group leader
Experimental hematology
Chiara Bonini, Group leader
Experimental hepatology
Giovanni Sitia, Group leader
Experimental Immunology
Giulia Casorati, Group leader
Functional genomics of cancer
Giovanni Tonon, Group leader
Gene transfer technologies and new gene therapy strategies
Luigi Naldini, Group leader
Genomics of the innate immune system
Renato Ostuni, Group leader
Immuno-biotherapy of melanoma and solid tumors
Vincenzo Russo, Group leader
Immunopathology
Luca Guidotti, Group leader
Innovative immunotherapies
Monica Casucci, Group leader
Lymphocyte activation
Anna Mondino, Group leader
Tumor biology and vascular targeting
Angelo Corti, Group leader
Tumor immunology
Maria Pia Protti, Group leader
The program gather together 5 clinical units of IRCCS Ospedale San Raffaele:
- Hepatobiliary surgery - Head: Luca Aldrighetti
- Anatomic pathology and histopathology - Head: Claudio Doglioni
- Pancreatic surgery - Head: Massimo Falconi
- Oncology - Head of pancreatic oncology: Michele Reni
- Diagnostic imaging – Head: Francesco De Cobelli
Monieri M, Rainone P, Sacchi A, Gori A, Gasparri AM, Coliva A, Citro A, Ferrara B, Policardi M, Valtorta S, Pocaterra A, Alfano M, Sheppard D, Piemonti L, Moresco RM, Corti A*, Curnis F*. A stapled chromogranin A-derived peptide homes in on tumors that express αvβ6 or αvβ8 integrins. Int J Biol Sci. 2023; 19(1):156-166. doi:10.7150/ijbs.76148. (*Corresponding Authors)
Corti A, Anderluzzi G, Curnis F. Neuropilin-1 and Integrins as Receptors for Chromogranin A-Derived Peptides. Pharmaceutics. 2022 Dec; 14(12): 2555. doi: 10.3390/pharmaceutics14122555.
Tran NL*, Ferreira LM*, Alvarez-Moya B*, Buttiglione V, Ferrini B, Zordan P, Monestiroli A, Fagioli C, Bezzecchi E, Scotti GM, Esposito A, Leone R, Gnasso C, Brendolan A, Guidotti LG, Sitia G. Continuous sensing of IFNα by hepatic endothelial cells shapes a vascular antimetastatic barrier. Elife. 2022 Oct 25;11:e80690. doi: 10.7554/eLife.80690. (* equal contribution)
Montaldo E, Lusito E, Bianchessi V, Caronni N, Scala S, Basso-Ricci L, Cantaffa C, Masserdotti A, Barilaro M, Barresi S, Genua M, Vittoria FM, Barbiera G, Lazarevic D, Messina C, Xue E, Marktel S, Tresoldi C, Milani R, Ronchi P, Gattillo S, Santoleri L, Di Micco R, Ditadi A, Belfiori G, Aleotti F, Naldini MM, Gentner B, Gardiman E, Tamassia N, Cassatella MA, Hidalgo A, Kwok I, Ng LG, Crippa S, Falconi M, Pettinella F, Scapini P, Naldini L, Ciceri F, Aiuti A, Ostuni R. Cellular and transcriptional dynamics of human neutrophils at steady state and upon stress. Nat Immunol. 2022 Oct;23(10):1470-1483. doi: 10.1038/s41590-022-01311-1.
Ferrara B, Dugnani E, Sordi V, Pasquale V, Pellegrini S, Reni M, Balzano G, Piemonti L. A Comprehensive Characterization of Stemness in Cell Lines and Primary Cells of Pancreatic Ductal Adenocarcinoma. Int J Mol Sci. 2022 Sep 14;23(18):10663. doi: 10.3390/ijms231810663.
Delfanti G, Cortesi F, Perini A, Antonini G, Azzimonti L, de Lalla C, Garavaglia C, Squadrito ML, Fedeli M, Consonni M, Sesana S, Re F, Shen H, Dellabona P, Casorati G. TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells. Sci Immunol. 2022 Aug 12;7(74):eabn6563. doi: 10.1126/sciimmunol.abn6563.
Corti A, Calimeri T, Curnis F, Ferreri AJM. Targeting the Blood-Brain Tumor Barrier with Tumor Necrosis Factor-α. Pharmaceutics. 2022 Jul 6;14(7):1414. doi: 10.3390/pharmaceutics14071414.
Faccani C, Rotta G, Clemente F, Fedeli M, Abbati D, Manfredi F, Potenza A, Anselmo A, Pedica F, Fiorentini G, Villa C, Protti MP, Doglioni C, Aldrighetti L, Bonini C, Casorati G, Dellabona P, de Lalla C. Workflow for high-dimensional flow cytometry analysis of T cells from tumor metastases. Life Science Alliance. Jun 2022, 5 (10) e202101316. doi: 10.26508/lsa.202101316.
Iannacone M, Andreata F, Guidotti LG. Immunological insights in the treatment of chronic hepatitis B. Curr Opin Immunol. 2022 May 16;77:102207. doi: 10.1016/j.coi.2022.102207.
Sitia G, Fiordaliso F, Violatto MB, Alarcon JF, Talamini L, Corbelli A, Ferreira LM, Tran NL, Chakraborty I, Salmona M, Parak WJ, Diomede L, Bigini P. Food-Grade Titanium Dioxide Induces Toxicity in the Nematode Caenorhabditis elegans and Acute Hepatic and Pulmonary Responses in Mice. Nanomaterials (Basel). 2022 May 13;12(10):1669. doi: 10.3390/nano12101669.
Delfanti G, Dellabona P, Casorati G, Fedeli M. Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment. Front Med (Lausanne). 2022 May 9;9:897750. doi: 10.3389/fmed.2022.897750.
Fumagalli V, Venzin V, Di Lucia P, Moalli F, Ficht X, Ambrosi G, Giustini L, Andreata F, Grillo M, Magini D, Ravà M, Friedrich C, Fontenot JD, Bousso P, Gilmore SA, Khan S, Baca M, Vivier E, Gasteiger G, Kuka M, Guidotti LG†, Iannacone M†. Group 1 ILCs regulate T cell-mediated liver immunopathology by controlling local IL-2 availability. Sci Immunol. 2022 Feb 25;7(68):eabi6112. doi: 10.1126/sciimmunol.abi6112. (†Co-Last Authors)
Aiolfi R*, Sitia G*, Iannacone M, Brunetta I, Guidotti LG, Ruggeri ZM. Arenaviral infection causes bleeding in mice due to reduced serotonin release from platelets. Science Signaling 2022 Feb 22;15(722):eabb0384. doi: 10.1126/scisignal.abb0384. (*equal contribution)
Ruggiero E, Carnevale E, Prodeus A, Magnani ZI, Camisa B, Merelli I, Politano C, Stasi L, Potenza A, Cianciotti BC, Manfredi F, Di Bono M, Vago L, Tassara M, Mastaglio S, Ponzoni M, Francesca Sanvito, Liu D, Balwani I, Galli R, Genua M, Ostuni R, Doglio M, O'Connell D, Dutta I, Yazinski SA, McKee M, Arredouani MS, Schultes B, Ciceri F, Bonini C. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve anti-tumor T cell function. Sci Transl Med. 2022 Feb 9;14(631):eabg8027. doi: 10.1126/scitranslmed.abg8027.
Pocaterra A, Catucci M, and Mondino A. Adoptive T cell therapy of solid tumors: time to team up with immunogenic chemo/radiotherapy. Curr Opin Immunol. 2022 Feb;74:53-59. doi: 10.1016/j.coi.2021.10.004.
De Sanctis F, Lamolinara A, Boschi F, Musiu C, Caligola S, Trovato R, Fiore A, Frusteri C, Anselmi C, Poffe O, Cestari T, Canè S, Sartoris S, Giugno R, Del Rosario G, Zappacosta B, Del Pizzo F, Fassan M, Dugnani E, Piemonti L, Bottani E, Decimo I, Paiella S, Salvia R, Lawlor RT, Corbo V, Park Y, Tuveson DA, Bassi C, Scarpa A, Iezzi M, Ugel S, Bronte V. Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. J Immunother Cancer. 2022 Jan;10(1):e003549. doi: 10.1136/jitc-2021-003549.
Greco B, Malacarne V, De Girardi F, Scotti GM, Manfredi F, Angelino E, Sirini C, Camisa B, Falcone L, Moresco MA, Paolella K, Di Bono M, Norata R, Sanvito F, Arcangeli S, Doglioni C, Ciceri F, Bonini C, Graziani A, Bondanza A, Casucci M. Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy 1 against solid malignancies. Sci Transl Med. 2022 Jan 19;14(628):eabg3072.. doi: 10.1126/scitranslmed.abg3072.
Fumagalli V, Ravà M, Marotta D, Di Lucia P, Laura C, Sala E, Grillo M, Bono E, Giustini L, Perucchini C, Mainetti M, Sessa A, Garcia-Manteiga JM, Donnici L, Manganaro L, Delbue S, Broccoli V, De Francesco R, D'Adamo P, Kuka M, Guidotti LG†, Iannacone M†. Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion. Sci Immunol. 2021 Nov 23:eabl9929. doi: 10.1126/sciimmunol.abl9929. (†Co-Last Authors)
Tedesco M, Giannese F, Lazarević D, Giansanti V, Rosano D, Monzani S, Catalano I, Grassi E, Zanella ER, Botrugno OA, Morelli L, Panina Bordignon P, Caravagna G, Bertotti A, Martino G, Aldrighetti L, Pasqualato S, Trusolino L, Cittaro D, Tonon G. Chromatin Velocity reveals epigenetic dynamics by single-cell profiling of heterochromatin and euchromatin. Nat Biotechnol. 2021 Oct 11.doi: 10.1038/s41587-021-01031-1.
Greco R, Lorentino F, Albanese S, Stanghellini MTL, Giglio F, Piemontese S, Clerici D, Lazzari L, Marcatti M, Mastaglio S, Xue E, Farina F, Pavesi F, Assanelli A, Carrabba MG, Marktel S, Vago L, Bonini C, Corti C, Bernardi M, Ciceri F, Peccatori J. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. Transplant Cell Ther 2021 09; 27: 776.e1-776.e13. doi: 10.1016/j.jtct.2021.05.023.
Fedeli M, Kuka M, Finardi A, Albano F, Viganò V, Iannacone M, Furlan R, Dellabona P, Casorati G. miR-21 sustains CD28 signalling and low-affinity T-cell responses at the expense of self-tolerance. Clin Transl Immunology. 2021 Sep 21;10(9):e1321. doi: 10.1002/cti2.1321.
Conforti A, Marra E, Palombo F, Roscilli G, Ravà M, Fumagalli V, Muzi A, Maffei M, Luberto L, Lione L, Salvatori E, Compagnone M, Pinto E, Pavoni E, Bucci F, Vitagliano G, Stoppoloni D, Pacello ML, Cappelletti M, Ferrara FF, D'Acunto E, Chiarini V, Arriga R, Nyska A, Di Lucia P, Marotta D, Bono E, Giustini L, Sala E, Perucchini C, Paterson J, Ryan KA, Challis AR, Matusali G, Colavita F, Caselli G, Criscuolo E, Clementi N, Mancini N, Groß R, Seidel A, Wettstein L, Münch J, Donnici L, Conti M, De Francesco R, Kuka M, Ciliberto G, Castilletti C, Capobianchi MR, Ippolito G, Guidotti LG, Rovati L, Iannacone M, Aurisicchio L. COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. Mol Ther. 2021 Sep 20:S1525-0016(21)00466-4. doi: 10.1016/j.ymthe.2021.09.011.
De Simone G, Andreata F, Bleriot C, Fumagalli V, Laura C, Garcia-Manteiga JM, Di Lucia P, Gilotto S, Ficht X, De Ponti FF, Bono EB, Giustini L, Ambrosi G, Mainetti M, Zordan P, Bénéchet AP, Ravà M, Chakarov S, Moalli F, Bajenoff M, Guidotti LG, Ginhoux F, Iannacone M. Identification of a Kupffer cell subset capable of reverting the T cell dysfunction induced by hepatocellular priming. Immunity. 2021 Sep 14;54(9):2089-2100.e8. doi: 10.1016/j.immuni.2021.05.005.
Ferrara B, Pignatelli C, Cossutta M, Citro A, Courtyì J, Piemonti L. The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options. Cancers (Basel). 2021 Sep 3;13(17):4442. doi: 10.3390/cancers13174442.
Grioni M, Brevi A, Cattaneo E, Rovida A, Bordini J, Bertilaccio MTS, Ponzoni M, Casorati G, Dellabona P, Ghia P, Bellone M,Calcinotto A. CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism. Blood Adv 2021 07; 5: 2817-2828. doi: 10.1182/bloodadvances.2020003795.
Ratti F, Casadei-Gardini A, Cipriani F, Fiorentini G, Pedica F, Burgio V, Cascinu S, Aldrighetti L. Laparoscopic Surgery for Intrahepatic Cholangiocarcinoma: A Focus on Oncological Outcomes. J Clin Med. 2021 Jun 26;10(13):2828. doi: 10.3390/jcm10132828.
Cilenti F*, Barbiera G*, Caronni N, Iodice D, Montaldo E, Barresi E, Lusito E, Cuzzola V, Vittoria FM, Mezzanzanica L, Miotto P, Di Lucia P, Lazarevic D, Cirillo DM, Iannacone M, Genua M^, Ostuni R^. A PGE2-MEF2A axis enables context-dependent control of inflammatory gene expression. IMMUNITY. 2021 June 14. doi:10.1016/j.immuni.2021.05.01. (*= equal contribution ^=equal contribution)
Manfredi F, Abbati D, Cianciotti BC, Stasi L, Potenza A, Ruggiero E, Magnani Z, Carnevale E, Doglio M, Noviello M, Tassi E, Balestrieri C, Buonanno S, Clemente F, De Lalla C, Protti MP, Mondino A, Casorati G, Dellabona P, Bonini C. Flow cytometry data mining by cytoChain identifies determinants of exhaustion and stemness in TCR-engineered T cells. Eur J Immunol. 2021 Jun 3. doi: 10.1002/eji.202049103.
Sacchi A, Gasparri AM, Monieri M, Anderluzzi G , Colombo B , Gori A, Corti A* and Curnis F*. Nanogold functionalized with lipoamide-isoDGR: a simple, robust and versatile nanosystem for avb3-integrin targeting Front Chem. 2021 May 28;9:690357. doi: 10.3389/fchem.2021.690357. (* Co-Corresponding Author)
Talamini L, Picchetti P, Ferreira LM, Sitia G, Russo L, Violatto MB, Travaglini L, Fernandez Alarcon J, Righelli L, Bigini P and De Cola L. Organosilica Cages Target Hepatic Sinusoidal Endothelial Cells Avoiding Macrophage Filtering. ACS Nano. 2021 May 19. doi:10.1021/acsnano.1c00316.
Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol. 2021 May 17. doi: 10.1038/s41577-021-00549-4.
Corti A*, Sacchi A, Gasparri AM, Monieri M , Anderluzzi G, Colombo B, Gori A, Mondino A and Curnis F*. Enhancement of doxorubicin anti-cancer activity by vascular targeting using IsoDGR/cytokine-coated nanogold. J Nanobiotechnology. 2021 May 5;19(1):128. doi:10.1186/s12951-021-00871-y. (* Co-Corresponding Author)
Exley MA, Dellabona P, Casorati G. Exploiting CD1-restricted T cells for clinical benefit. MOL IMMUNOL 2021 Feb; 132: 126-131. doi: 10.1016/j.molimm.2020.12.015.
Ratti F, Cipriani F, Fiorentini G, Burgio V, Ronzoni M, Della Corte A, Cascinu S, De Cobelli F, and Aldrighetti L. Evolution of surgical treatment of Colorectal Liver Metastases 2in the real world: single center experience in 1212 cases. CANCERS 2021 Mar 9;13(5):1178. doi: 10.3390/cancers13051178.
Caronni N, Montaldo E, Mezzanzanica L, Cilenti F, Genua M, Ostuni R. Determinants, mechanisms, and outcomes of myeloid cell diversity in cancer. IMMUNOL REV 2021 Feb 9. doi: 10.1111/imr.12944.
Maspes A, Pizzetti F, Rossetti A, Makvandi P, Sitia G, Rossi F. Advances in Bio-Based Polymers for Colorectal CancerTreatment: Hydrogels and Nanoplatforms. Gels. 2021 Jan 11;7(1):6. doi: 10.3390/gels7010006.
Reni M, Andreasi V , Gasparri AM , Dugnani E , Colombo B, Macchini M, Bianco M, Dallatomasina A, Citro A, Assi E, Protti MP, Esposito A, Falconi M, Curnis F, Piemonti L, and Corti A. Circulating chromogranin A is cleaved into vasoregulatory fragments in patients with pancreatic ductal adenocarcinoma. Front Oncol. 2020 Dec 23;10:613582. doi: 10.3389/fonc.2020.613582.
Fumagalli V, Di Lucia P, Venzin V, Bono EB, Jordan R, Frey CR, Delaney W, Chisari FV, Guidotti LG†, Iannacone M†. Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection. J Exp Med. 2020 Nov 2;217(11):e20200298. doi: 10.1084/jem.20200298. (†Co-Last Authors)
Corti A, Gasparri AM, Sacchi A, Colombo B, Monieri M, Rrapaj E, Ferreri AJM, Curnis F. NGR-TNF Engineering with an N-Terminal Serine Reduces Degradation and Post-Translational Modifications and Improves Its Tumor-Targeting Activity. Mol Pharm. 2020 Oct 5;17(10):3813-3824. doi: 10.1021/acs.molpharmaceut.0c00579.
Protti MP, De Monte L. Thymic stromal lymphopoietin and Cancer: Th2-dependent and -independent mechanisms. Front Immunol. 2020 Sep 16;11:2088. doi: 10.3389/fimmu.2020.02088.
Ficht X, Iannacone M. Immune surveillance of the liver by T cells. Sci Immunol. 2020 Sep 4;5(51):eaba2351. doi: 10.1126/sciimmunol.aba2351.
Manfredi F, Cianciotti BC, Potenza A, Tassi E, Noviello E, Biondi A, Ciceri F, Bonini C*, Ruggiero E.* TCR redirected T cells for cancer treatment: Acheivements, hurdles and goals. Front Immunol. 2020 Sep 3;11:1689. doi: 10.3389/fimmu.2020.01689. (*= equal contribution)
McGrath E, Chabannon C, Terwel S, Bonini C, Kuball J. Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life. Current Opinion in Oncology: Sep 2020 - Volume 32 - Issue 5 - p 427-433 doi: 10.1097/CCO.0000000000000665.
Arcangeli S*, Mestermann K*, Weber J*, Bonini C^, Casucci M^, Michael M.^ Overcoming key challenges in engineered T cell cancer immunotherapy. Current Opinion in Oncology. 2020 Sep;32(5):398-407. doi: 10.1097/CCO.0000000000000664. (*= equal contribution ^=equal contribution).
De Giovanni M, Cutillo V, Giladi A, Sala E, Maganuco CG, Medaglia C, Di Lucia P, Bono E, Cristofani C, Consolo E, Giustini L, Fiore A, Eickhoff S, Kastenmüller W, Amit I, Kuka M, Iannacone M. Spatiotemporal regulation of type I interferon expression determines the antiviral polarization of CD4+ T cells. NAT IMMUNOL 2020 Mar; 21: 321-330. doi: 10.1038/s41590-020-0596-6.
Protti, MP and De Monte L. Dual Role of Inflammasome Adaptor ASC in Cancer.Front Cell Dev Bio 2020 Feb; 8: Article 40. doi: 10.3389/fcell.2020.00040.
Nardelli F, Ghitti M, Quilici G, Gori A, Luo Q, Berardi A, Sacchi A, Monieri M, Bergamaschi G, Bermel W, Chen F, Corti A, Curnis F, Musco G. A stapled chromogranin A-derived peptide is a potent dual ligand for integrins αvβ6 and αvβ8. CHEM COMMUN 2019 Dec; 55: 14777-14780. doi: 10.1039/c9cc08518a.
Mahata SK, Corti A. Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation. ANN NY ACAD SCI 2019 Nov; 1455: 34-58. doi: 10.1111/nyas.14249.
Gasparri AM, Sacchi A, Basso V, Cortesi F, Freschi M, Rrapaj E, Bellone M, Casorati G, Dellabona P, Mondino A, Corti A, Curnis F. Boosting Interleukin-12 Antitumor Activity and Synergism with Immunotherapy by Targeted Delivery with isoDGR-Tagged Nanogold. SMALL 2019 Nov; 15: e1903462. doi: 10.1002/smll.201903462.
Comoli P, Chabannon C, Koehl U, Lanza F, Urbano-Ispizua A, Hudecek M, Ruggeri A, Secondino S, Bonini C, Pedrazzoli P. Development of adaptive immune effector therapies in solid tumors. Ann Oncol. 2019 Nov 1;30(11):1740-1750. doi: 10.1093/annonc/mdz285.
Bénéchet AP, De Simone G, Di Lucia P, Cilenti F, Barbiera G, Le Bert N, Fumagalli V, Lusito E, Moalli F, Bianchessi V, Andreata F, Zordan P, Bono E, Giustini L, Bonilla WV, Bleriot C, Kunasegaran K, Gonzalez-Aseguinolaza G, Pinschewer DD, Kennedy PTF, Naldini L, Kuka M, Ginhoux F, Cantore A, Bertoletti A, Ostuni R, Guidotti LG, Iannacone M. Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming. Nature. 2019 Oct;574(7777):200-205. doi: 10.1038/s41586-019-1620-6.
Total Publications: 51
Total IF: 893.114
Mean IF: 17.512
Last update: 30/12/2022